Kristina L. Bajema
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kristina L. Bajema has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ann Thomas
Oregon Public Health Division , Portland, Oregon , USA
1 shared publicationArthur L Reingold
School of Public Health, University of California , Berkeley, California , USA
1 shared publication- Bernard Beall
Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA
1 shared publication - Cynthia Lucero-Obusan
Office of Public Health, US Department of Veterans Affairs, Veterans Health Administration
1 shared publication Kari E Burzlaff
New York State Department of Health , Albany, New York , USA
1 shared publicationLee H Harrison
Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland , USA
1 shared publication
Latest Publications
- Open Access
- 28 April 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (2) , 342-351
Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States
Background: Antibiotic-nonsusceptible invasive pneumococcal disease (NS-IPD) incidence declined dramatically in the United States after introduction of pneumococcal conjugate vaccines (PCVs) into the infant immunization schedule (7-valent PCV7 in 2000, replaced by the 13-valent PCV13 in 2010). We evaluated the long-term impact of PCVs on NS-IPD. Methods: We identified IPD cases through the Centers for Disease Control Active Bacterial Core surveillance during 1998–2018. Isolates intermediate or resistant to ≥1 antibiotic class were classified as nonsusceptible. We calculated annual rates of IPD (cases per 100 000 persons). Results: From 1998 through 2018, NS-IPD incidence decreased from 43.9 to 3.2 among children <5 years and from 19.8 to 9.4 among adults ≥65 years. Incidence of vaccine-type NS-IPD decreased in all age groups, whereas incidence of nonvaccine type (NVT) NS-IPD increased in all age groups; the greatest absolute increase in NVT NS-IPD occurred among adults ≥65 years (2.3 to 7.2). During 2014–2018, NVTs 35B, 33F, 22F, and 15A were the most common NS-IPD serotypes. Conclusions: Nonsusceptible IPD incidence decreased after PCV7 and PCV13 introduction in the United States. However, recent increases in NVT NS-IPD, most pronounced among older adults, have been observed. New higher valency PCVs containing the most common nonsusceptible serotypes, including 22F and 33F, could help further reduce NS-IPD.
- 28 April 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (2) , 342-351
Open AccessImpact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States
Background: Antibiotic-nonsusceptible invasive pneumococcal disease (NS-IPD) incidence declined dramatically in the United States after introduction of pneumococcal conjugate vaccines (PCVs) into the infant immunization schedule (7-valent PCV7 in 2000, replaced by the 13-valent PCV13 in 2010). We evaluated the long-term impact of PCVs on NS-IPD. Methods: We identified IPD cases through the Centers for Disease Control Active Bacterial Core surveillance during 1998–2018. Isolates intermediate or resistant to ≥1 antibiotic class were classified as nonsusceptible. We calculated annual rates of IPD (cases per 100 000 persons). Results: From 1998 through 2018, NS-IPD incidence decreased from 43.9 to 3.2 among children <5 years and from 19.8 to 9.4 among adults ≥65 years. Incidence of vaccine-type NS-IPD decreased in all age groups, whereas incidence of nonvaccine type (NVT) NS-IPD increased in all age groups; the greatest absolute increase in NVT NS-IPD occurred among adults ≥65 years (2.3 to 7.2). During 2014–2018, NVTs 35B, 33F, 22F, and 15A were the most common NS-IPD serotypes. Conclusions: Nonsusceptible IPD incidence decreased after PCV7 and PCV13 introduction in the United States. However, recent increases in NVT NS-IPD, most pronounced among older adults, have been observed. New higher valency PCVs containing the most common nonsusceptible serotypes, including 22F and 33F, could help further reduce NS-IPD.
- Open Access
- 10 December 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (49) , 1700-1705
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021
This report describes vaccine effectiveness in preventing COVID-19-associated hospitalizations among U.S. veterans.
- 10 December 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (49) , 1700-1705
Open AccessComparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021
This report describes vaccine effectiveness in preventing COVID-19-associated hospitalizations among U.S. veterans.
- Open Access
- 14 February 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (6) , 166-170
Persons Evaluated for 2019 Novel Coronavirus — United States, January 2020
Health care providers should remain vigilant about possible 2019 novel coronavirus (2019-nCoV) exposures not only among returning travelers from China, but also among those in close contact with persons with 2019-nCoV in the United States.
- 14 February 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (6) , 166-170
Open AccessPersons Evaluated for 2019 Novel Coronavirus — United States, January 2020
Health care providers should remain vigilant about possible 2019 novel coronavirus (2019-nCoV) exposures not only among returning travelers from China, but also among those in close contact with persons with 2019-nCoV in the United States.